Ligand Pharma (LGND) Tops Q4 EPS by 53c ; Offers Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/1/2026
- Wall Street closes sharply lower as AI cash burn fears spark tech selloff
- Amazon burns cash, Intel flags weak PC demand as AI boom's costs ripple across markets
- Bitcoin, cryptocurrency prices fall after Binance reports security issue
- Higher yields now hurting AI stock bull as bond markets police capex: BofA
- Oil jumps 2%, settles at 6-month highs on fears of escalation in Iran
Tweet
Share
E-mailGet Alerts LGND Hot Sheet
Price: $322.75 +1.71%
Financial Fact:
Decrease (increase) in liability for contingent value rights: -958K
Today's EPS Names:
OPY, BNCC, ZVOI, More
Financial Fact:
Decrease (increase) in liability for contingent value rights: -958K
Today's EPS Names:
OPY, BNCC, ZVOI, More
Join SI Premium – FREE
Ligand Pharma (NASDAQ: LGND) reported Q4 EPS of $2.02, $0.53 better than the analyst estimate of $1.49. Revenue for the quarter came in at $59.66 million versus the consensus estimate of $55.59 million.
GUIDANCE:
Ligand Pharma sees FY2026 EPS of $8.00-$9.00, versus the consensus of $8.42. Ligand Pharma sees FY2026 revenue of $245-285 million, versus the consensus of $265.7 million.
For earnings history and earnings-related data on Ligand Pharma (LGND) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Goldman Sachs Updates US Conviction List Directors' Cut
- This Swiss stock is ‘well positioned to deliver’ profitable growth: Citi
- New Break Resources plans $550,000 flow-through share offering
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
